$BPTH
BIO-PATH HOLDINGS, INC.

2015 Q2 Form 10-Q Financial Statement

#000114420415029223 Filed on May 11, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $570.0K $790.0K $380.0K
YoY Change -24.0% 107.89% 58.33%
% of Gross Profit
Research & Development $564.0K $593.0K $107.6K
YoY Change 9.08% 450.91% -73.16%
% of Gross Profit
Depreciation & Amortization $50.00K $10.00K $0.00
YoY Change 25.0% -100.0%
% of Gross Profit
Operating Expenses $1.131M $1.379M $510.2K
YoY Change -11.28% 170.28% -22.21%
Operating Profit -$1.131M -$1.379M -$510.2K
YoY Change -11.28% 170.28% -22.21%
Interest Expense $10.00K $0.00 $10.00K
YoY Change 0.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $5.000K $4.000K $5.334K
YoY Change -17.0% -25.01% -5897.83%
Pretax Income -$1.130M -$1.370M -$500.0K
YoY Change -11.02% 174.0% -24.24%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.126M -$1.375M -$504.9K
YoY Change -11.25% 172.34% -23.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$2.511M -$3.044M -$1.111M
COMMON SHARES
Basic Shares Outstanding 89.76M shares 89.76M shares 89.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.08M $12.45M $16.82M
YoY Change -29.52% -25.98% 5700.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $950.0K $480.0K $157.5K
YoY Change 453.73% 204.83% 4.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.03M $12.94M $17.23M
YoY Change -24.97% -24.88% 3815.07%
LONG-TERM ASSETS
Property, Plant & Equipment $92.56K $102.8K
YoY Change
Goodwill
YoY Change
Intangibles $1.171M $1.211M $1.371M
YoY Change -12.07% -11.71%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.263M $1.310M $1.371M
YoY Change -5.15% -4.47% -10.37%
TOTAL ASSETS
Total Short-Term Assets $12.03M $12.94M $17.23M
Total Long-Term Assets $1.263M $1.310M $1.371M
Total Assets $13.29M $14.25M $18.60M
YoY Change -23.45% -23.38% 844.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $385.1K $80.00K $238.0K
YoY Change 387.96% -66.39% 240.04%
Accrued Expenses $310.0K $539.7K $78.88K
YoY Change 107.58% 584.21% -64.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $690.0K $616.2K $420.0K
YoY Change 106.88% 46.74% 44.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $690.0K $616.2K $420.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $690.0K $616.2K $420.0K
YoY Change 106.88% 46.74% 44.81%
SHAREHOLDERS EQUITY
Retained Earnings -$22.42M
YoY Change
Common Stock $89.76K $89.24K
YoY Change 0.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.60M $13.63M $18.18M
YoY Change
Total Liabilities & Shareholders Equity $13.29M $14.25M $18.60M
YoY Change -23.47% -23.38% 844.04%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$1.126M -$1.375M -$504.9K
YoY Change -11.25% 172.34% -23.04%
Depreciation, Depletion And Amortization $50.00K $10.00K $0.00
YoY Change 25.0% -100.0%
Cash From Operating Activities -$1.370M -$1.410M -$544.4K
YoY Change 24.55% 158.99% -1.19%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $13.81M
YoY Change -100.0% 4418.79%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 $13.81M
YoY Change -100.0% 4418.79%
NET CHANGE
Cash From Operating Activities -1.370M -1.410M -$544.4K
Cash From Investing Activities $0.00
Cash From Financing Activities 0.000 0.000 $13.81M
Net Change In Cash -1.370M -1.410M $13.27M
YoY Change 24.55% -110.63% -5508.01%
FREE CASH FLOW
Cash From Operating Activities -$1.370M -$1.410M -$544.4K
Capital Expenditures $0.00
Free Cash Flow -$544.4K
YoY Change -1.19%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 bpth Accrued Liabilities Related Parties Current
AccruedLiabilitiesRelatedPartiesCurrent
67050 USD
CY2014Q4 us-gaap Cash
Cash
13858798 USD
CY2014Q4 us-gaap Other Inventory
OtherInventory
154667 USD
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
100494 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
14113959 USD
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123410 USD
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
123410 USD
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20568 USD
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10284 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102842 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
113126 USD
CY2015Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1210737 USD
CY2014Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1250893 USD
CY2015Q1 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
0 USD
CY2014Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
100450 USD
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
539668 USD
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
253445 USD
CY2015Q1 bpth Accrued Liabilities Related Parties Current
AccruedLiabilitiesRelatedPartiesCurrent
0 USD
CY2015Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0 USD
CY2014Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
100000 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
616224 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
561971 USD
CY2015Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2015Q1 us-gaap Liabilities
Liabilities
616224 USD
CY2015Q1 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
21291883 USD
CY2014Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
19917245 USD
CY2014Q4 us-gaap Liabilities
Liabilities
561971 USD
CY2015Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
89763 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
89763 USD
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
34834775 USD
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
34743489 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
13632655 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
14916007 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14248879 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15477978 USD
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2014Q1 us-gaap Revenues
Revenues
0 USD
CY2015Q1 us-gaap Revenues
Revenues
0 USD
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.74
CY2014Q1 bpth Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
15000000 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4400000 USD
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0200 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0174 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.45 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y8M12D
CY2013Q4 bpth Authorised Capital To Be Raised
AuthorisedCapitalToBeRaised
100000000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2014Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
15000000 USD
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
13800000 USD
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
435500 USD
CY2015Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89762872 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89762872 shares
CY2015Q1 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
76556 USD
CY2014Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
41026 USD
CY2014Q1 bpth Common Stock Repurchased Shares
CommonStockRepurchasedShares
2500000 shares
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
107641 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
592481 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
380850 USD
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
786412 USD
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
510210 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
1378893 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13812373 USD
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13812373 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2014Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
13267951 USD
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
BIO-PATH HOLDINGS INC
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001133818
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-510210 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1378893 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-504876 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89237872 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
89762872 shares
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
100000 USD
CY2014Q4 bpth Accounts Payable And Accrued Liabilities Related Party Current
AccountsPayableAndAccruedLiabilitiesRelatedPartyCurrent
67050 USD
CY2014Q1 bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
370000 USD
CY2015Q1 bpth Drug Product Testing Agreement Consideration To Be Paid In Stages
DrugProductTestingAgreementConsiderationToBePaidInStages
190000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
362000 USD
CY2015Q1 bpth Supply Agreement Consideration To Be Paid In Stages
SupplyAgreementConsiderationToBePaidInStages
430000 USD
CY2014Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
40156 USD
CY2015Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
40156 USD
CY2014Q1 us-gaap Depreciation
Depreciation
0 USD
CY2015Q1 us-gaap Depreciation
Depreciation
10284 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
86278 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
91286 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
197692 USD
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
204230 USD
CY2014Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
93347 USD
CY2015Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
22142 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
125059 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
54253 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-544422 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1405031 USD
CY2015Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-1405031 USD
CY2013Q4 us-gaap Cash
Cash
3551832 USD
CY2014Q1 us-gaap Cash
Cash
16819783 USD
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Trading Symbol
TradingSymbol
BPTH
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89762872 shares
CY2015Q1 bpth Payments For Project Fees
PaymentsForProjectFees
440000 USD
CY2014Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
86278 USD
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91286 USD

Files In Submission

Name View Source Status
0001144204-15-029223-index-headers.html Edgar Link pending
0001144204-15-029223-index.html Edgar Link pending
0001144204-15-029223.txt Edgar Link pending
0001144204-15-029223-xbrl.zip Edgar Link pending
bpth-20150331.xml Edgar Link completed
bpth-20150331.xsd Edgar Link pending
bpth-20150331_cal.xml Edgar Link unprocessable
bpth-20150331_def.xml Edgar Link unprocessable
bpth-20150331_lab.xml Edgar Link unprocessable
bpth-20150331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v409609_10q.htm Edgar Link pending
v409609_ex31.htm Edgar Link pending
v409609_ex32.htm Edgar Link pending